TickerTalks
Browse all tickers →
TickerTalks›$ACB
ACACB

Aurora Cannabis Inc.

$ACB·$254M·Drug Manufacturers - Specialty & Generic·Healthcare
$4.10-1.4%YTD-4.9%1Y-19.7%
Price updated 3d ago·X counts updated 14h ago
ACACB
$ACBAurora Cannabis Inc.
$4.10-1.44%80 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $ACB on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

80X posts · last 7 days
Sep 10Sep 27
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $ACB's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 54% of tracked names.

Bearish sentimentAI analysisGenerated by AI from underlying data9 posts analyzed · as of 2026-09-15

Curaleaf's myth-vs-fact rebuttal continues to frame ACB management as rejecting a 45% premium and 'acting like a deer in headlights'. Posters describe Aurora as attacking the CURA offer with misleading narratives while its own record shows dilution and declining guidance.

Read what X is saying about $ACB

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $ACB — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventEvent coming upAI verdict · as of 2026-09-28

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Curaleaf's hostile bid at ~45% premium rejected — Aurora files at Alberta Securities Commission calling disclosure deficient.

The story is entirely the M&A fight — everything else is context for how it resolves.

  • Curaleaf hostile takeover bid rejected by Aurora management (45% premium framing on X).
  • Aurora filed with Alberta Securities Commission alleging disclosure deficiencies in Curaleaf's bid; Safari Flower Company accretive acquisition + European growth cited as standalone case.
  • Tape: -4.9% YTD, -19.7% t12m; 37% of 52w range, above 50-day (+16.5%), above 200-day (+13.9%).
  • Fundamentals still ugly: PE -2.5x, op margin -30%, FCF yield -17.0% — the takeover offer is the value.
  • X calls management 'deer in headlights' rejecting a 45% premium — real shareholder-side skepticism.
  • Q1 FY27 EPS -$0.05 vs -$0.13 (a smaller loss, +64.6%); revenue $47.6M in line.

Watch 11/4 print, ASC ruling on Curaleaf disclosure, and any competing bid or Curaleaf sweetener.

Agrees with X sentimentThe X frame is right — a management team rejecting a 45% premium without a competing offer is exactly the fact pattern shareholders push back on. The regulatory-complaint route buys time, not a better deal.

What to watch: 11/4 earnings, ASC decision on Curaleaf's disclosure, any competing bid, tender-offer response rates, and Safari Flower integration progress.

On the calendar: 2026-11-04

Read the AI verdict on $ACB

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Canadian cannabis producer selling dried flower, oils, and edibles to medical and adult-use markets across Canada and internationally.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - Specialty & Generic sits in its cycle right now — and what that implies for $ACB.

Drug Manufacturers - Specialty & Generic · Healthcare

Specialty pharma is bifurcating — GLP-1 adjacent programs attract premium valuations while generic manufacturers face pricing erosion from FDA approval backlogs clearing. Biosimilar launches of adalimumab (Humira), ustekinumab, and etanercept are accelerating branded erosion timelines, while mid-tier specialty pharma focuses on complex generics (ophthalmic, inhalation) to sustain margins.

What this means for $ACB

Neutral — Canadian cannabis producer selling dried flower, oils, and edibles to medical and adult-use markets across Canada and internationally.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+20.6%YTD
+48.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-15.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-29.7%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-17.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-21.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
32.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$-0.05$-0.13+64.6%
Q1 2026Jun 11, 2026$-0.71$-0.07-914.1%
Q4 2025Feb 4, 2026$0.02$0.10-75.9%
Q3 2025Nov 5, 2025$-0.65$0.03-2274.8%
Next earningsWed, Nov 4·consensus EPS $-0.03

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY27$67.6M-23.4%-5.9%-70.2%$-0.07$-9.9M
Q4 FY26$38.1M-57.9%47.8%-66.1%$-0.99$-5.4M
Q3 FY26$94.2M+6.8%49.5%5.1%$0.03$11.0M
Q2 FY26$90.4M+11.4%35.7%-20.2%$-0.91$-46.7M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY27$292.6M$285.7M – $298.7M-$0.17-$0.18 – -$0.165
FY28$319.3M$308.2M – $337.9M$0.11$0.10 – $0.113
FY29$353.0M$336.2M – $382.1M$0.23$0.14 – $0.393
FY30$428.3M$413.4M – $453.1M$0.40$0.38 – $0.432
FY31$464.2M$448.1M – $491.2M$0.66$0.63 – $0.711

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.37%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+16.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+13.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 61.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.455-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

No material 8-K / SC 13D / S-3 / 424B5 filings in the last 180 days.

+ 34 other (27 6-Ks · 2 SC14D9F/As · 1 F-X · 1 SC14D9F) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Curaleaf's Hostile Takeover Attempt of Aurora Cannabis Is Hitting Turbulence. Here's What Investors Should Watch.fool.com·2d agoAurora Cannabis Files Application with Alberta Securities Commission to Protect Company Shareholders Having Identified Several Deficiencies in Curaleaf's Hostile Bid Disclosureprnewswire.com·5d agoAurora Cannabis Provides Business Update; Accretive Acquisition of Safari Flower Company and Leading European Performance Expected to Fuel International Growth in the Fiscal Second Quarter 2027 and Beyondprnewswire.com·12d agoCuraleaf Tries To Roll Up Aurora In a Hostile Cannabis Bidmarketbeat.com·13d agoAurora Cannabis Refutes Curaleaf's Latest Attempt To Distract Shareholders From The Factsgurufocus.com·14d ago

More in Drug Manufacturers - Specialty & Generic

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$EVO$TEVA$ZTS$INDV$ELAN$CRON$PRGO$HROW
Voices on X · last 7 days

No standout posts about $ACB on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport